Aura Biosciences, Inc. — Investor Relations & Filings

Aura Biosciences is a clinical-stage biotechnology company developing a new class of targeted therapies for solid tumors. The company's proprietary platform creates Virus-Like Drug Conjugates (VDCs), which use Virus-Like Particles to selectively deliver anti-cancer agents to tumor cells. This approach is designed to destroy cancer while preserving healthy tissue and organ function. Aura's initial focus is on ocular and urologic oncology, with a lead program for the first-line treatment of choroidal melanoma, a rare, vision-threatening eye cancer that lacks approved drug therapies. The company aims to establish a new standard of care across multiple cancer indications.